Article
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
European journal of pharmacology - 15 Apr 2021
Lu Tingting, Cao Jiangyan, Zou Fengming, Li Xixiang, Wang Aoli, Wang Wenliang, Liang Huamin, Liu Qingwang, Hu Chen, Chen Cheng, Hu Zhenquan, Wang Wenchao, Li Lili, Ge Jian, Shen Yang, Ren Tao, Liu Jing, Xia Ruixiang, Liu Qingsong
Abstract excerpt
As the critical driving force for chronic myeloid leukemia (CML), BCR gene fused ABL kinase has been extensively explored as a validated target of drug discovery. Although imatinib has achieved tremendous success as the first-line treatment for CML, the long-term application ultimately leads to resistance, primarily via various acquired mutations occurring in the BCR-ABL kinase. Although dasatinib and nilotinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.